IMB 071703
Alternative Names: IMB-071703Latest Information Update: 15 Jul 2024
At a glance
- Originator Beijing Immunoah Pharma Tech
- Class Antibodies; Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen antagonists; CD40 ligand stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours